Adenoma de pituitaria

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

ID	`DIS-PITUITARY-ADENOMA`
Tipo	Enfermedad
Aliaces	Adenoma de corticotropoAdenoma hipófisis asociado a MEN1Nonfunctioning pituitary adenomaPitNETTumor neuroendocrino de pituitaria- ProlactinomaAdenoma de somatotrópicoАденома гіпофіза
Situación	reviewed 2026-05-18 \| pending_clinical_signoff
Enfermedades	Ninguna declarada
Fuentes	`SRC-NCCN-CNS-2025` `SRC-NCCN-NET-2025`

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology	8272/0
icd_o_3_topography	["C75.1"]
icd_10	D35.2
who_classification	WHO Endocrine and Neuroendocrine Tumours 5th ed (2022) + CNS 5th ed (2021): Pituitary neuroendocrine tumor (PitNET) lineage-based classification — lactotroph / somatotroph / corticotroph / thyrotroph / gonadotroph / null-cell

Capacidades

Notas

Functional adenomas classified by lineage / hormone hypersecretion; treatment is endocrine-cohort-specific: prolactinoma — dopamine agonists (cabergoline > bromocriptine) first-line, surgery for resistant / intolerant; somatotroph (acromegaly) — transsphenoidal surgery first-line, somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR), GH-receptor antagonist (pegvisomant) for residual; corticotroph (Cushing disease) — surgery, pasireotide, ketoconazole / metyrapone / osilodrostat for cortisol control; nonfunctioning — surgery for mass effect / visual compromise. MEN1 carriers: cascade screening from age 5 (prolactin + IGF-1 + serum Ca + intact PTH + fasting gastrin + pituitary MRI per protocol).

Utilizado por

Algoritmos

ALGO-MEN1-CARRIER-SURVEILLANCE - ALGO-MEN1-CARRIER-SURVEILLANCE
ALGO-PITUITARY-ADENOMA-1L - ALGO-PITUITARY-ADENOMA-1L

Enfermedad

DIS-PARATHYROID-CARCINOMA - Carcinoma paratiroideo
DIS-PITUITARY-BLASTOMA - Blastoma de pituitaria

Fármaco

DRUG-CABERGOLINE - Cabergoline
DRUG-PASIREOTIDE - Pasireotide

Indicación

IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA - IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA
IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL - IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL
IND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECT - IND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECT
IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE - IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE

Señal de alerta

RF-PITUITARY-MASS-EFFECT-VISUAL-COMPROMISE - Pituitary adenoma (typically nonfunctioning macroadenoma) causing compressive mass effect...

Esquema terapéutico

REG-CABERGOLINE-PROLACTINOMA - Cabergoline para el prolactinoma (agonista de dopamina, de primera línea)
REG-PASIREOTIDE-CUSHING - Pasireotide para la enfermedad de Cushing (terapia médica dirigida por la hipofisis)
REG-SSA-ACROMEGALY - Analógico de la somatostatina para la acromegalia (lanreotide de primera generación SSA; pasireotide donde dice SS...